PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NUW5XXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTDU5l4UUN3ME2wMlAzOjd4IN88US=> MX\TRW5ITVJ?
CHP-212 NFy4epJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\aW3VFUUN3ME2wMlAzQDh3IN88US=> MXXTRW5ITVJ?
EoL-1-cell NILMeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ITWM2OD1yLkC0NVUzKM7:TR?= MULTRW5ITVJ?
DU-4475 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEe1PVkh|ryP NGjpcGNUSU6JRWK=
MMAC-SF MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G5O2lEPTB;MD6xNFk4PCEQvF2= MVTTRW5ITVJ?
AGS M4\HUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMUG3NVMh|ryP NUTZdJhlW0GQR1XS
M14 NVnUNJgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\VTWM2OD1yLkG1OFY5KM7:TR?= MlXhV2FPT0WU
CP50-MEL-B NF\QNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;NNGlEPTB;MD6xO|I2PCEQvF2= MmTvV2FPT0WU
C32 NH3ZSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17HSmlEPTB;MD6xPVA4OiEQvF2= MXPTRW5ITVJ?
KMOE-2 NG\GeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHGTWM2OD1yLkG5O|k2KM7:TR?= NFjSeYZUSU6JRWK=
A101D Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PoVmlEPTB;MD6yNVQh|ryP Ml60V2FPT0WU
KM12 NVywXZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[zcnZKSzVyPUCuNlQxPTdizszN NXPw[Gt1W0GQR1XS
HSC-4 NHn3cWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMkSzPVUh|ryP NWnvUGRMW0GQR1XS
NOMO-1 MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTSTWM2OD1yLkK1O|QzKM7:TR?= NES2W5ZUSU6JRWK=
MZ7-mel Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXyUIxKSzVyPUCuNlY{PCEQvF2= NXziN41kW0GQR1XS
ACN M4HseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;BcWlEPTB;MD6yOlc{PyEQvF2= MmDUV2FPT0WU
MEL-HO NIDMdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMke2OVIh|ryP MWPTRW5ITVJ?
BHT-101 NHLqUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nM[2lEPTB;MD6yPFYxPiEQvF2= MnvwV2FPT0WU
SK-MEL-28 NGqzVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHpUHlKSzVyPUCuN|A1ODlizszN NX3MU3FRW0GQR1XS
KG-1 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXFbXNNUUN3ME2wMlMxPjZ6IN88US=> MWrTRW5ITVJ?
COLO-679 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13x[mlEPTB;MD6zNlczKM7:TR?= MVXTRW5ITVJ?
SK-MEL-24 M125O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvleHZKSzVyPUCuN|I5OTNizszN NYHabHppW0GQR1XS
G-361 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH6TWM2OD1yLkO2O|k2KM7:TR?= MoLYV2FPT0WU
KY821 M{TiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwM{e5NUDPxE1? MXvTRW5ITVJ?
KASUMI-1 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwM{m5JO69VQ>? NVzMOYNRW0GQR1XS
HL-60 NX35W5VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln4TWM2OD1yLkSxNVA4KM7:TR?= NEP0enlUSU6JRWK=
K5 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwNEOxNVch|ryP NWO2RWtYW0GQR1XS
KU812 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;xTWM2OD1yLkS1Nlk6KM7:TR?= MmHNV2FPT0WU
SH-4 M1mwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fve2lEPTB;MD60OlI2PiEQvF2= NFzOTVVUSU6JRWK=
HTC-C3 NWjNeVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLWUYZKSzVyPUCuOFY2OzFizszN M16yNnNCVkeHUh?=
CP66-MEL Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTxfphMUUN3ME2wMlQ5QDB7IN88US=> MXHTRW5ITVJ?
WM-115 NFLJZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNEmyOVch|ryP MnT2V2FPT0WU
A2780 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNEm4NlMh|ryP NWTGToh1W0GQR1XS
P12-ICHIKAWA MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfqTWM2OD1yLk[xNlIyKM7:TR?= NInMS3NUSU6JRWK=
HMV-II Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTGTWM2OD1yLk[0OFY2KM7:TR?= NXvqT3BVW0GQR1XS
HT-144 NHvm[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofDTWM2OD1yLk[0OlU4KM7:TR?= NHP4SYdUSU6JRWK=
LB2518-MEL NEHVU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\TOXdKSzVyPUCuO|E3OzJizszN Mmq3V2FPT0WU
NCI-SNU-1 M2PRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHryVIRKSzVyPUCuO|U1OzNizszN M3:zN3NCVkeHUh?=
C2BBe1 NEHzVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Do[WlEPTB;MD64NVAzOyEQvF2= M{S3fXNCVkeHUh?=
PSN1 M2X6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwOU[xPVYh|ryP M{HZfXNCVkeHUh?=
UACC-257 NWPabHdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFryfY5KSzVyPUCuPVY1PzNizszN NUPjVHdkW0GQR1XS
RVH-421 M{TSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7SfFdKSzVyPUCuPVcyQCEQvF2= M2ewXHNCVkeHUh?=
GP5d MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rOdGlEPTB;MD65PFMxQCEQvF2= NHS4[mpUSU6JRWK=
TYK-nu NVvpTYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmiwTWM2OD1zLkCzNVczKM7:TR?= MWHTRW5ITVJ?
SK-N-AS NUfKU3p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMEe5OFch|ryP MoH5V2FPT0WU
SW620 NHi4cJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWxU|c3UUN3ME2xMlE{PTN2IN88US=> Mm\HV2FPT0WU
HuP-T4 M3zFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2xTWM2OD1zLkG4N|U6KM7:TR?= MVXTRW5ITVJ?
A549 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT5TWM2OD1zLkG5OVc3KM7:TR?= M{LjPHNCVkeHUh?=
Mewo NHnvZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;2fXZTUUN3ME2xMlIxOjd4IN88US=> MlXlV2FPT0WU
ONS-76 NELzVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwMkKwOFkh|ryP MXLTRW5ITVJ?
SK-MEL-1 NYT3eopIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnHTWM2OD1zLkKzOFE6KM7:TR?= M12zdXNCVkeHUh?=
RCM-1 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfJTWM2OD1zLkK0NFQ4KM7:TR?= NVHDUnp7W0GQR1XS
H-EMC-SS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnuTWM2OD1zLkK5OlA5KM7:TR?= MWDTRW5ITVJ?
NCI-H2291 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwM{K1N|Yh|ryP NHvnZnBUSU6JRWK=
SW1463 NGrscXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwM{O3NlEh|ryP MkjwV2FPT0WU
LS-411N NX\FRodiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPCWZRKSzVyPUGuOFA2OTdizszN MljHV2FPT0WU
BV-173 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfifVFFUUN3ME2xMlQ1ODF3IN88US=> NE\nW2tUSU6JRWK=
LS-513 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPIXHhKSzVyPUGuOFUyQTJizszN NFrBWZFUSU6JRWK=
LoVo MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjaRnV{UUN3ME2xMlQ3Ozl7IN88US=> MVPTRW5ITVJ?
HO-1-N-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzJS2VKSzVyPUGuOVE3OzRizszN M1rzVHNCVkeHUh?=
ML-2 M3ThSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwNUK4Olgh|ryP Mkf4V2FPT0WU
NCI-H1437 NWLTTJpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fFfGlEPTB;MT61OVI4PSEQvF2= NWT3cFBtW0GQR1XS
SW1116 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUO2ZpUUN3ME2xMlU3Ozl6IN88US=> MnzpV2FPT0WU
A4-Fuk NXnaU5dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fCcWlEPTB;MT61O|A1PSEQvF2= M3i4OnNCVkeHUh?=
HD-MY-Z MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVToN5NWUUN3ME2xMlU4Ozd4IN88US=> NX[2cVRUW0GQR1XS
SK-MEL-2 M2LuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\wNpF{UUN3ME2xMlU4PDV7IN88US=> Ml\rV2FPT0WU
RT-112 M3;zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;WOHVKSzVyPUGuOVg6PTJizszN M2\CUHNCVkeHUh?=
COLO-829 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD5TWM2OD1zLk[yNlMzKM7:TR?= Mn\JV2FPT0WU
OVCAR-5 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPVS4VEUUN3ME2xMlc4Pjh5IN88US=> NX\aeVU4W0GQR1XS
NB69 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GyemlEPTB;MT63PFQ3QSEQvF2= NEPEOZBUSU6JRWK=
NCI-H292 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPsTWM2OD1zLki2Olk6KM7:TR?= M1fWWnNCVkeHUh?=
LOXIMVI M2S0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;4[GlEPTB;MT64PVQzPyEQvF2= MoDaV2FPT0WU
BPH-1 NHn2XFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzQclhKSzVyPUGuPFk2QTFizszN MUDTRW5ITVJ?
A375 M1z4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm5XGh3UUN3ME2xMlg6PzF2IN88US=> NIPJdHRUSU6JRWK=
LCLC-97TM1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33UUGlEPTB;MT65NlI2PiEQvF2= MmXIV2FPT0WU
RXF393 NHrq[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13vSGlEPTB;MT65O|g5PyEQvF2= NW\tR5JUW0GQR1XS
HCC70 NFL3R5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDnTWM2OD1{LkCyOFI3KM7:TR?= NUDv[HhkW0GQR1XS
EM-2 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGwTWM2OD1{LkC3NVk5KM7:TR?= MoLhV2FPT0WU
MZ2-MEL NUXqXoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LiW2lEPTB;Mj6xNVEzPyEQvF2= MonNV2FPT0WU
HN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfIdIVKSzVyPUKuNVYzPzhizszN NFLZbI9USU6JRWK=
A2058 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfGbW9vUUN3ME2yMlE6Ojd7IN88US=> M3mydHNCVkeHUh?=
NB7 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwM{SwPFYh|ryP M{nqZXNCVkeHUh?=
DOK M3\QRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJwM{W3O|Mh|ryP MXvTRW5ITVJ?
CAL-27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHSWJdKSzVyPUKuN|kzOzZizszN MVPTRW5ITVJ?
BB65-RCC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPSTWM2OD1{LkSwOlc1KM7:TR?= MXrTRW5ITVJ?
RD MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXraN|l6UUN3ME2yMlQ1PzJ|IN88US=> MknWV2FPT0WU
KNS-62 NEfzd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwNUGxOlQh|ryP MUDTRW5ITVJ?
EW-13 NUn1WmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX1TWM2OD1{LkW2N|M6KM7:TR?= M2rNNXNCVkeHUh?=
DB NEj3dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3UU3JXUUN3ME2yMlU5Pzh6IN88US=> MX3TRW5ITVJ?
HCC2218 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwNkS3O|gh|ryP MnLIV2FPT0WU
L-363 NHyyVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn0NXdKSzVyPUKuO|Q{PyEQvF2= MlT3V2FPT0WU
CHL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHmTWM2OD1{LkiwO|g2KM7:TR?= MYDTRW5ITVJ?
BFTC-905 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvMdZVbUUN3ME2yMlgzPTNizszN NHe1bYpUSU6JRWK=
HCE-T M3zJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPPVmJKSzVyPUKuPFMzPjRizszN M2rzOXNCVkeHUh?=
COLO-792 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\IeG1KSzVyPUKuPFQxOjdizszN MYXTRW5ITVJ?
LB2241-RCC NUn0ZVliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwOEW4PVMh|ryP M2q3T3NCVkeHUh?=
CAL-39 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPBTWM2OD1{Lki5PVk6KM7:TR?= MlnjV2FPT0WU
T-24 M2CxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHqTWM2OD1{LkmxNVEzKM7:TR?= NF:2OJBUSU6JRWK=
NCI-H727 NVf6WJJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\tNHRWUUN3ME2yMlkyPzl4IN88US=> M3nTVXNCVkeHUh?=
Ca9-22 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTvTGVpUUN3ME2yMlk4OjV3IN88US=> M2TPcXNCVkeHUh?=
MIA-PaCa-2 NHOx[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwMEC3PFEh|ryP NXvDTXdKW0GQR1XS
HT-1080 NGXibo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNwMEG5PVch|ryP MkfHV2FPT0WU
D-423MG NX3id5l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoraTWM2OD1|LkC3O|U{KM7:TR?= NFywR25USU6JRWK=
LAMA-84 NHHHPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNwMUO1PEDPxE1? MV;TRW5ITVJ?
SW780 NH:3dGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe0WoEyUUN3ME2zMlE1OjJ7IN88US=> NW\YPJV2W0GQR1XS
KU-19-19 NUPJO4J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliwTWM2OD1|LkG3NFM1KM7:TR?= NX\HcYc5W0GQR1XS
COLO-741 NILh[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\RWWlEPTB;Mz6xPFY4OyEQvF2= M4r2U3NCVkeHUh?=
HSC-3 M3PQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXSTWM2OD1|LkKzNVUyKM7:TR?= MnPHV2FPT0WU
SN12C NYjU[|NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTxT4k2UUN3ME2zMlI1PzBzIN88US=> M2HITHNCVkeHUh?=
786-0 NY\kd|Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfxTmFOUUN3ME2zMlI4OjR|IN88US=> M4THOXNCVkeHUh?=
GAK NEj1Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLFbGo2UUN3ME2zMlMzPTZzIN88US=> NInD[oFUSU6JRWK=
PANC-03-27 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SxeWlEPTB;Mz6zOVA1PSEQvF2= NIXse5dUSU6JRWK=
CTB-1 NGDOWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwNEewOFch|ryP NETJZY9USU6JRWK=
A427 M2\iW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXNUnpxUUN3ME2zMlU6PTV4IN88US=> M1fLTHNCVkeHUh?=
EGI-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLNTWM2OD1|Lk[wOVg{KM7:TR?= NXrpTlg5W0GQR1XS
U-2-OS M{m2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC0UmlKSzVyPUOuOlczPTZizszN MYPTRW5ITVJ?
NCI-SNU-5 M{O0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\JS2lEPTB;Mz62O|c{KM7:TR?= NXH2T|Z3W0GQR1XS
SK-LU-1 M{S1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6xUWJKSzVyPUOuOlg4QThizszN Ml:0V2FPT0WU
697 M2OzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTQcJh4UUN3ME2zMlY6PjB|IN88US=> MXHTRW5ITVJ?
HPAF-II MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDBTWM2OD1|Lke1OFkh|ryP MlvLV2FPT0WU
NCI-H2087 NGfrWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHORlJXUUN3ME2zMlg1Pjd{IN88US=> MVjTRW5ITVJ?
SK-MEL-3 NET0[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf6TWM2OD1|Lki1NVU1KM7:TR?= NIXPTWNUSU6JRWK=
CGTH-W-1 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHGTJFVUUN3ME2zMlg2PzJ3IN88US=> MWrTRW5ITVJ?
8505C M3vneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHTTWM2OD1|LkmwNFc5KM7:TR?= MU\TRW5ITVJ?
GAMG NV3zc2dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XJOmlEPTB;ND6wNlM4PyEQvF2= NHzXeWRUSU6JRWK=
SW626 NV;DTmV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnThTWM2OD12LkC0OFgh|ryP M2W4VHNCVkeHUh?=
CAL-62 M{\wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjzeJhXUUN3ME20MlA4PDNizszN M1vXWHNCVkeHUh?=
MHH-PREB-1 M4DkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwMUKxNVEh|ryP NW[zR41[W0GQR1XS
RPMI-7951 NVXKNItpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLMdplKSzVyPUSuNlU2QDlizszN MoTjV2FPT0WU
HOP-92 NFjnTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jsVWlEPTB;ND6yOVY4KM7:TR?= MoPaV2FPT0WU
MDA-MB-231 M3zvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jLRWlEPTB;ND6yPVIzOyEQvF2= NFHWNWtUSU6JRWK=
LAN-6 NXTsXoF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KwRWlEPTB;ND6zNVY{PyEQvF2= M4DiRnNCVkeHUh?=
ALL-PO NGTBNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r3V2lEPTB;ND6zOlE2PiEQvF2= M2XxRnNCVkeHUh?=
HH MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO3[nZbUUN3ME20MlQyPTl5IN88US=> MmrlV2FPT0WU
IGROV-1 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELJPWhKSzVyPUSuOFUyPzFizszN NIO3b4hUSU6JRWK=
NCI-H358 NYj6XVNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;w[FdyUUN3ME20MlQ2Ozh3IN88US=> NF\pVm5USU6JRWK=
NB5 NXSwd29nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPVTWM2OD12Lk[wN|Y6KM7:TR?= MlHlV2FPT0WU
NCI-H747 M1rmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DzSWlEPTB;ND62PFgxPyEQvF2= Mne4V2FPT0WU
NH-12 M4q1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnhU4lKSzVyPUSuO|E3OjVizszN NYT5NmRSW0GQR1XS
LB1047-RCC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;uTWM2OD12LkezPFE2KM7:TR?= NH\MWJRUSU6JRWK=
EFO-27 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwN{i2Olch|ryP M{O1U3NCVkeHUh?=
EPLC-272H NIPZb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nOWWlEPTB;ND65PVY3QSEQvF2= NIjjTI5USU6JRWK=
CAL-54 NWrxOmppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP2TlhKSzVyPUWuNFI3QTVizszN MoHjV2FPT0WU
H4 M4nXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojHTWM2OD13LkC0NlU2KM7:TR?= NX70dlJ3W0GQR1XS
MOLT-13 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7WTWM2OD13LkC2O|c3KM7:TR?= NV7BdY1xW0GQR1XS
CAL-33 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TrfGlEPTB;NT6xNlMyPyEQvF2= NYj6Z4JVW0GQR1XS
23132-87 NGHSdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\vVFVKSzVyPUWuNVY5PzJizszN Mn;DV2FPT0WU
UM-UC-3 NIDV[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jwe2lEPTB;NT6xPFA1PyEQvF2= NH\DWnhUSU6JRWK=
HuH-7 NIXCRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGxR3VmUUN3ME21MlI4OTR5IN88US=> MYXTRW5ITVJ?
BCPAP MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTVwM{K5Olkh|ryP NW\MZ|NIW0GQR1XS
AsPC-1 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{exfmlEPTB;NT6zOlc3OyEQvF2= NXfiWW8{W0GQR1XS
NCI-H1155 NEfNT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3qTWM2OD13LkSwNFUyKM7:TR?= NYLTTJpOW0GQR1XS
GT3TKB NV;QRpVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rsNGlEPTB;NT60OlU6QCEQvF2= NIK0SlZUSU6JRWK=
HCC2998 NV7HPJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjufIJKSzVyPUWuOFkyODlizszN MmfBV2FPT0WU
NUGC-3 NWL6TWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;BTWM2OD13LkS5N|AzKM7:TR?= M4LOS3NCVkeHUh?=
Hs-578-T MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDqTWM2OD13LkWzO|k1KM7:TR?= M1rGcnNCVkeHUh?=
FADU NWr3Spo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLxOWNTUUN3ME21MlU2PzJ4IN88US=> MXTTRW5ITVJ?
NBsusSR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnJZm1uUUN3ME21MlU4OTV3IN88US=> NEj4VFNUSU6JRWK=
ME-180 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jLc2lEPTB;NT61PFA6OiEQvF2= NInnemhUSU6JRWK=
SW1710 NGnFVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rWOmlEPTB;NT62NVY2PCEQvF2= M{HMbnNCVkeHUh?=
HuP-T3 NWDyVGp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\JTWM2OD13Lk[yNFI6KM7:TR?= MlXlV2FPT0WU
HOS NEf6W5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\5TWM2OD13Lk[yPVI{KM7:TR?= MYTTRW5ITVJ?
PA-1 NY\K[nF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL6dYZKSzVyPUWuOlQzPjVizszN MoDSV2FPT0WU
LU-99A MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO4OFFyUUN3ME21MlY3PDVzIN88US=> NInXRoJUSU6JRWK=
RS4-11 NWnPToJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H0d2lEPTB;NT62Olc4PSEQvF2= MkD3V2FPT0WU
TE-8 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTVwNki1N|ch|ryP NVLYOGNpW0GQR1XS
RERF-LC-MS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwNki4NFMh|ryP NU\rXIs6W0GQR1XS
MEL-JUSO M{nufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnOWldsUUN3ME21Mlc{PzhizszN NXfsNJNGW0GQR1XS
SK-MES-1 NWPicol3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTsTWM2OD13LkizOVI5KM7:TR?= M3zRSHNCVkeHUh?=
D-263MG M{\mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfiTWM2OD13Lki4N|UyKM7:TR?= NVyxeJdlW0GQR1XS
NB10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTuTWM2OD13Lki5OFYh|ryP MknZV2FPT0WU
SK-HEP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTVwOUO0O|Eh|ryP M3\BfHNCVkeHUh?=
HT-29 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTVwOUixNVgh|ryP MX7TRW5ITVJ?
KYSE-140 NVfEUFh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTZwMEKxPFIh|ryP MV;TRW5ITVJ?
NCI-H1666 NGjPPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnFfIxRUUN3ME22MlA5PDZzIN88US=> NFP3[|BUSU6JRWK=
NCI-H1304 NXHoTGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;qTnpKSzVyPU[uNVk6PCEQvF2= NE[4XI9USU6JRWK=
RPMI-8866 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\W[JpjUUN3ME22MlIyOzF|IN88US=> NWL2XpZ6W0GQR1XS
MV-4-11 M3X6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof5TWM2OD14LkKzNVk6KM7:TR?= MXTTRW5ITVJ?
A431 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Tq[GlEPTB;Nj6yOFI6PiEQvF2= MnzzV2FPT0WU
PANC-10-05 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfzTWM2OD14LkK4N|Y{KM7:TR?= NHuyblVUSU6JRWK=
TK10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDGTWM2OD14LkOyOlA1KM7:TR?= MUHTRW5ITVJ?
NCI-H1975 NGXI[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX3TWM2OD14LkS3NlE2KM7:TR?= MXHTRW5ITVJ?
A172 M17SN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorZTWM2OD14LkS5NVc3KM7:TR?= MmjxV2FPT0WU
D-566MG MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXGOVVKSzVyPU[uOVQ{ODNizszN M2izUXNCVkeHUh?=
NCI-H2122 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDiTWtMUUN3ME22MlYyPTJ6IN88US=> NGLxfFlUSU6JRWK=
COR-L105 NYfZ[VFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOxeHJKSzVyPU[uOlUzPzVizszN NGXUOpBUSU6JRWK=
AN3-CA NV25T28zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jhbmlEPTB;Nj62PFY1OSEQvF2= MWfTRW5ITVJ?
Calu-6 NWfRWZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGflNVdKSzVyPU[uO|k3QThizszN Mn25V2FPT0WU
HCT-116 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW3fldZUUN3ME22MlgyOjZ2IN88US=> MnPzV2FPT0WU
MHH-NB-11 NUjRcGpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nvXmlEPTB;Nj64OVAxOiEQvF2= NVu3[2I{W0GQR1XS
MFE-280 NEXDdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m4PGlEPTB;Nj64OVk5OyEQvF2= NVHLcotWW0GQR1XS
SW1088 M{\wRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13SXWlEPTB;Nj65NVkyOyEQvF2= NXX4ToFpW0GQR1XS
SW48 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXh[4RKSzVyPU[uPVQ2OSEQvF2= NYrNcZpxW0GQR1XS
HuCCT1 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTdwMEGwN|ch|ryP NITEXmJUSU6JRWK=
ACHN MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3VbZdQUUN3ME23MlAzQTR|IN88US=> NXfTSVliW0GQR1XS
8305C M4K3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTdwMEm5PVUh|ryP NWTGWlNCW0GQR1XS
DoTc2-4510 NYTMd4JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTPTWM2OD15LkGyNVUh|ryP M{HGVXNCVkeHUh?=
COR-L23 NIXwUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTdwMkS0NkDPxE1? M{jBUXNCVkeHUh?=
SK-MEL-30 M4jH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HhXmlEPTB;Nz6yOVA5OyEQvF2= NGDjPWFUSU6JRWK=
BE-13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTdwM{O4N|Qh|ryP NGHZbnNUSU6JRWK=
GR-ST MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzKWJlKSzVyPUeuOFAyPzRizszN MYTTRW5ITVJ?
LU-135 M2i0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;sXWJTUUN3ME23MlU2QTN7IN88US=> NUX2N5JXW0GQR1XS
U-266 M1;xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLpTWM2OD15LkW2Nlg3KM7:TR?= M3rzO3NCVkeHUh?=
NCI-H1355 M3ewOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTdwNUi2N|Uh|ryP NVexbGJiW0GQR1XS
NB14 M1Lpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL0fWFWUUN3ME23MlY3PjR{IN88US=> NXPuNFlWW0GQR1XS
SCC-25 NUDVNWs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjlVII2UUN3ME23MlcxQSEQvF2= NXPrSYRFW0GQR1XS
COLO-678 M1XwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzoTWM2OD15LkexNFc3KM7:TR?= NIPwUllUSU6JRWK=
TGBC1TKB NFzhXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zZ[WlEPTB;Nz64PVM6QCEQvF2= NVHWcGg4W0GQR1XS
IST-MEL1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TSVWlEPTB;OD6wNFQxPiEQvF2= NYfYdIgyW0GQR1XS
ECC10 M{DzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwMEOzPVUh|ryP M2ez[3NCVkeHUh?=
EW-16 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{eycmlEPTB;OD6wPFQ1PSEQvF2= MXjTRW5ITVJ?
DOHH-2 M3LrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRThwMkCwPVUh|ryP MW\TRW5ITVJ?
NCI-H1581 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13zPGlEPTB;OD6yOlMzOyEQvF2= NVfMcVA4W0GQR1XS
TE-5 MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T4cWlEPTB;OD60NlQzQSEQvF2= NH[4em1USU6JRWK=
CAKI-1 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnYNIx6UUN3ME24MlU4OjJ{IN88US=> MU\TRW5ITVJ?
A673 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zLVmlEPTB;OD62N|IxOiEQvF2= NWrYV3h3W0GQR1XS
CAL-12T M1q3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHTTWM2OD16Lk[1O|U{KM7:TR?= MnLmV2FPT0WU
DBTRG-05MG Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHheFVrUUN3ME24Mlc1QDV7IN88US=> MUnTRW5ITVJ?
SK-N-FI M1jZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v5ZmlEPTB;OD64NVM4QSEQvF2= MVfTRW5ITVJ?
K-562 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlewTWM2OD16LkizPVU4KM7:TR?= M3Swe3NCVkeHUh?=
SBC-1 NFrubWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRThwOE[2OFUh|ryP MoKyV2FPT0WU
ES4 NFnQZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThwOE[4PFQh|ryP M{HyWXNCVkeHUh?=
MS-1 M2Thdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRThwOEe1NVch|ryP NGjvWXBUSU6JRWK=
RKO M4L2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T2dmlEPTB;OD64PVA2PyEQvF2= MV;TRW5ITVJ?
NCI-H1693 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rhWmlEPTB;OD65NlE4KM7:TR?= M1W5ZXNCVkeHUh?=
SW954 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6xVoFKSzVyPUiuPVY6PzhizszN MWTTRW5ITVJ?
SK-UT-1 M4nZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjWXotKSzVyPUiuPVc3QDNizszN MUnTRW5ITVJ?
T98G NXfVXINGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33uWGlEPTB;OD65PVg1PiEQvF2= MkDqV2FPT0WU
NCI-H2126 NEHmZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTlwMEC4NlYh|ryP NWj3WIRSW0GQR1XS
TE-12 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrWTWM2OD17LkCzN|Y4KM7:TR?= NVzhZ2hKW0GQR1XS
DK-MG M3vsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon1TWM2OD17LkKxNVkyKM7:TR?= NFfDRXdUSU6JRWK=
MEG-01 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTsTWM2OD17LkK0PVMyKM7:TR?= M3HXN3NCVkeHUh?=
HCC1937 NWXDPVMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTlwMkmwPVEh|ryP M{XlO3NCVkeHUh?=
MKN45 NWPKdnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TEeGlEPTB;OT60OVA3PSEQvF2= NYCyRoRYW0GQR1XS
NCI-H1792 M{\kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTlwNEWyNVkh|ryP M{L6VHNCVkeHUh?=
SW1417 NH;Je3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\5NpdvUUN3ME25MlU3QDN5IN88US=> MVrTRW5ITVJ?
639-V MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjXRo9KSzVyPUmuOlQ{QDhizszN NWfvNY9sW0GQR1XS
P30-OHK M33lUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLGVnNKSzVyPUmuOlU{OTZizszN MV7TRW5ITVJ?
YKG-1 NWDL[|hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rDdWlEPTB;OT63OVA{OyEQvF2= M2XLbnNCVkeHUh?=
KGN NFrL[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqzTWM2OD17LkizO|k2KM7:TR?= MVHTRW5ITVJ?
MSTO-211H NHi2OmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Nc5ZRUUN3ME25Mlk2PTJ7IN88US=> NIfzT2ZUSU6JRWK=
NCI-H1573 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXGd3RmUUN3ME2xNE4yPTd2IN88US=> M1K0R3NCVkeHUh?=
NCI-H720 NXrQ[2xOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFradHJKSzVyPUGwMlE6QDlizszN NIDtVlhUSU6JRWK=
KARPAS-45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;LfGlEPTB;MUCuNlc6PSEQvF2= M{nWcXNCVkeHUh?=
MDA-MB-175-VII NEXBS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TXVGlEPTB;MUCuOFgh|ryP NYDP[pk4W0GQR1XS
SK-NEP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnzcHlKSzVyPUGwMlQ6QDFizszN MoHYV2FPT0WU
MKN28 NGTwb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFqyT3JKSzVyPUGwMlUyQCEQvF2= M1fI[HNCVkeHUh?=
KYSE-520 NITnWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2U2lEPTB;MUCuOVIh|ryP NVnZRVlrW0GQR1XS
KE-37 NYnEWIR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jzd2lEPTB;MUCuOVI4OiEQvF2= MmSxV2FPT0WU
VA-ES-BJ M2K2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPYZ29KSzVyPUGwMlU3PyEQvF2= NHnrc2dUSU6JRWK=
CCRF-CEM MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LPemlEPTB;MUCuOVY5PCEQvF2= MmHuV2FPT0WU
GMS-10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFyLk[wPVQh|ryP MYLTRW5ITVJ?
NCI-H1623 NUfXVW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXOUVZKSzVyPUGwMlY{PzlizszN MlLjV2FPT0WU
NEC8 NVi0WXlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nrdmlEPTB;MUCuO|c4OyEQvF2= NUjTVIY6W0GQR1XS
MOLT-16 NHHYVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzwe2dCUUN3ME2xNE45OTF|IN88US=> MVnTRW5ITVJ?
DJM-1 NYDlNo1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETVUYFKSzVyPUGxMlA{PzlizszN MU\TRW5ITVJ?
U251 M1XYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzKcm9KSzVyPUGxMlA1OiEQvF2= NXPURnljW0GQR1XS
SBC-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLBTWM2OD1zMT6xOFY4KM7:TR?= NHS0TW5USU6JRWK=
SW756 NEXOeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFzLkKxOVQh|ryP NWHVXG42W0GQR1XS
KS-1 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXK[ZlKSzVyPUGxMlI3OTlizszN NFjNdm5USU6JRWK=
SF295 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\jSY14UUN3ME2xNU4{OTB2IN88US=> NUXGT2sxW0GQR1XS
YH-13 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFzLkOyOlch|ryP MYrTRW5ITVJ?
SW837 NInYbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\qR2lKSzVyPUGxMlM2ODZizszN NHT5ZVZUSU6JRWK=
KYSE-450 NVLP[XI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXuZYNKSzVyPUGxMlQxPTdizszN NXvQbmFFW0GQR1XS
KYSE-180 NWTxcnR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\TdHRKSzVyPUGxMlQ5OiEQvF2= M3LJfnNCVkeHUh?=
S-117 M{\Z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD1zMT60PFk3KM7:TR?= NWH4[GxFW0GQR1XS
KOSC-2 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m1dmlEPTB;MUGuOlIzOiEQvF2= MUXTRW5ITVJ?
KYSE-270 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm0[5pVUUN3ME2xNU45PzR3IN88US=> NXexfYNIW0GQR1XS
D-336MG MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFzLkmwO|Uh|ryP MUDTRW5ITVJ?
KALS-1 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF{LkCwNVYh|ryP MlHoV2FPT0WU
LB373-MEL-D NFrDTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DHWWlEPTB;MUKuNFU{OyEQvF2= NWfLfnhDW0GQR1XS
HLE NXHpPItzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fTNmlEPTB;MUKuNFU5PSEQvF2= NH;ud|BUSU6JRWK=
SJSA-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF{LkC3N|Uh|ryP M2jYOXNCVkeHUh?=
SW1990 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3i[m5VUUN3ME2xNk4xQTFzIN88US=> MkXsV2FPT0WU
NOS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOzdlFKSzVyPUGyMlE{PTJizszN MYrTRW5ITVJ?
GI-ME-N NHj4cItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLFTWM2OD1zMj6yNVY{KM7:TR?= M{fuSHNCVkeHUh?=
NCI-H1703 M3nucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzFUWlKSzVyPUGyMlI3OTZizszN MVvTRW5ITVJ?
ES7 M2nuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF{LkK3NlQh|ryP M{\mO3NCVkeHUh?=
KYSE-510 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXSbWxKSzVyPUGyMlUxPzlizszN MlrsV2FPT0WU
BHY M{nN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX5Z2NKSzVyPUGyMlU{ODdizszN MUnTRW5ITVJ?
TCCSUP NHXveIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF{LkW3OVch|ryP M1e3bHNCVkeHUh?=
HSC-2 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDtd2lKSzVyPUGyMlU6QTZizszN NEPJ[opUSU6JRWK=
BEN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfFTWM2OD1zMj62NVQ{KM7:TR?= NFnC[mNUSU6JRWK=
769-P NUjIdpBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzIUpBKSzVyPUGyMlc6OjRizszN MXfTRW5ITVJ?
HT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOwT2ZKUUN3ME2xNk45OzR4IN88US=> M33NWXNCVkeHUh?=
LXF-289 M1PL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF{Lkm1N|Eh|ryP Mnj1V2FPT0WU
OVCAR-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\ocnJKSzVyPUGyMlk2PjdizszN MX;TRW5ITVJ?
ATN-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF|LkCxPFQh|ryP NUXvXYE3W0GQR1XS
8-MG-BA NYG4fWlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF|LkC0OVUh|ryP NFntSYpUSU6JRWK=
SW13 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonQTWM2OD1zMz6xNVY2KM7:TR?= MV3TRW5ITVJ?
NCI-H1092 NELDZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF|LkG2NkDPxE1? NE\tTHNUSU6JRWK=
OAW-42 NVjTbpcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF|LkG5N|ch|ryP M37oW3NCVkeHUh?=
NCI-H2452 NVPESHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n0b2lEPTB;MUOuNlE4PSEQvF2= MknvV2FPT0WU
CAPAN-1 NXvJZo1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF|LkW1NVQh|ryP NVTtfHViW0GQR1XS
NCI-H2009 NY\Cd|N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL1cXZTUUN3ME2xN{42QTF7IN88US=> NEnGNHNUSU6JRWK=
SF268 NF\l[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;ibGlEPTB;MUOuOlMzPiEQvF2= NFPTdodUSU6JRWK=
GCIY MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe0ZWl3UUN3ME2xN{43QTJ5IN88US=> NWHWU286W0GQR1XS
OS-RC-2 NIq4RohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164[WlEPTB;MUOuPVUxOSEQvF2= NV2zW4lYW0GQR1XS
GCT MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7KbpdTUUN3ME2xN{46Pjl5IN88US=> NHPEbIlUSU6JRWK=
NB17 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF2LkC4OUDPxE1? M4rUc3NCVkeHUh?=
NCI-H2030 M3LJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H5SGlEPTB;MUSuNVQ3PSEQvF2= NUPlSG13W0GQR1XS
HC-1 NInDWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnRfVZPUUN3ME2xOE4zODh5IN88US=> MU\TRW5ITVJ?
QIMR-WIL M{TTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7GT5lKSzVyPUG0MlM1OTJizszN MVPTRW5ITVJ?
Capan-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PZbWlEPTB;MUSuN|cyPCEQvF2= MlG3V2FPT0WU
BALL-1 M3HwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTiTWM2OD1zND60OlY2KM7:TR?= M33ieHNCVkeHUh?=
LS-1034 M{TBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7YVYFIUUN3ME2xOE43OTV{IN88US=> MnqwV2FPT0WU
U-118-MG MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLRTWM2OD1zND62N|Eh|ryP MmLQV2FPT0WU
NCI-H630 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF2Lk[1Olgh|ryP MYDTRW5ITVJ?
OVCAR-8 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HNeWlEPTB;MUSuO|IxOSEQvF2= NUX5bJpoW0GQR1XS
NCI-H2347 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF2LkiyN{DPxE1? NVjqO5JEW0GQR1XS
BT-549 NWjaWIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDQTWM2OD1zND64Nlg1KM7:TR?= NWfuV25lW0GQR1XS
LB831-BLC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF2Lki5N|Qh|ryP NF\hfHpUSU6JRWK=
NCI-H661 NXjaTIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\YU4RKSzVyPUG0Mlk2QSEQvF2= NFvsUldUSU6JRWK=
MKN7 NVizfVAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF3LkCwPVMh|ryP NHjoPXpUSU6JRWK=
U-87-MG NUfpZo52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHHOHBKSzVyPUG1MlA5QTdizszN MnnJV2FPT0WU
OVCAR-4 NUOydpZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe0W41xUUN3ME2xOU4yPDJ2IN88US=> MVzTRW5ITVJ?
OE33 NGn2OHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPiTWM2OD1zNT6xO|EyKM7:TR?= Mke3V2FPT0WU
EC-GI-10 M2K1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L5XWlEPTB;MUWuNlM2PyEQvF2= MmHzV2FPT0WU
AM-38 NVS1[|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXtbpExUUN3ME2xOU4zPzF5IN88US=> NGLi[HJUSU6JRWK=
NCI-H1563 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TWbWlEPTB;MUWuN|Q6KM7:TR?= NGC4W2xUSU6JRWK=
SCC-4 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF3LkSxNFMh|ryP Moj2V2FPT0WU
Detroit562 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\UVGZZUUN3ME2xOU41PTR5IN88US=> NECyS5VUSU6JRWK=
PC-14 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjITWM2OD1zNT60PFY3KM7:TR?= M1Pa[HNCVkeHUh?=
ES3 NFHObo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzJTWM2OD1zNT61N|Yh|ryP M3vyT3NCVkeHUh?=
OCI-AML2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESxPW5KSzVyPUG1Mlc3OTRizszN MUXTRW5ITVJ?
LU-134-A NGPhNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF3LkmwNVgh|ryP MWfTRW5ITVJ?
SAS NYrNXXF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF3LkmzO|Mh|ryP M{izSXNCVkeHUh?=
TGBC11TKB MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvjbJlkUUN3ME2xOU46PDF2IN88US=> NEXvSVRUSU6JRWK=
HOP-62 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITkVJFKSzVyPUG1Mlk2QTdizszN NFTyUYxUSU6JRWK=
G-401 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv5TWM2OD1zNT65OlQ6KM7:TR?= M4fZR3NCVkeHUh?=
NCI-H28 NH6wV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF4LkC4OVYh|ryP NYXMR4ZsW0GQR1XS
A204 M{TTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rwfmlEPTB;MU[uNlAxPiEQvF2= NGThWopUSU6JRWK=
NCI-H1299 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfQ[GZKSzVyPUG2MlIzQTFizszN NHPPfmFUSU6JRWK=
VMRC-RCZ NUDId5hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPhTWM2OD1zNj6yOVkzKM7:TR?= MmrBV2FPT0WU
BxPC-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTBZm1KSzVyPUG2MlI5PTZizszN M1fHNHNCVkeHUh?=
NCI-H2228 M3;Femdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fhd2lEPTB;MU[uOVE2QCEQvF2= NF;ubXNUSU6JRWK=
NCI-H23 NXjTUFZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7jVJpKSzVyPUG2MlYxPzhizszN NIfndpBUSU6JRWK=
NKM-1 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF5LkCxPFkh|ryP NYfHc3ZrW0GQR1XS
KYSE-70 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF5LkK4PUDPxE1? MVPTRW5ITVJ?
BB49-HNC NHTL[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjRTWM2OD1zNz61Olg3KM7:TR?= NG\LT5VUSU6JRWK=
SCC-15 NFG1O5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TZfmlEPTB;MUeuPFQ4OyEQvF2= MYTTRW5ITVJ?
D-247MG NYGzPHViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrZTWM2OD1zNz65NlQ4KM7:TR?= M3;jVXNCVkeHUh?=
BB30-HNC NXLPRYZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;4TWM2OD1zOD6wN|E5KM7:TR?= MWjTRW5ITVJ?
CAL-85-1 M3LCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorBTWM2OD1zOD6xPFA6KM7:TR?= NVyzVGlxW0GQR1XS
HT-3 NF3YblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Gxe2lEPTB;MUiuN|k4PyEQvF2= NXz6[2FGW0GQR1XS
KYSE-410 NYT6T2FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6yNXZUUUN3ME2xPE41PTd5IN88US=> M4TmPHNCVkeHUh?=
SW982 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF6LkW2OFkh|ryP MYXTRW5ITVJ?
SW962 M4X5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnzcmI3UUN3ME2xPE42PzB{IN88US=> MnvoV2FPT0WU
Ramos-2G6-4C10 NHHw[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjcWlEPTB;MUiuOVkzPyEQvF2= M2\vRXNCVkeHUh?=
OC-314 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGxdnJKSzVyPUG4Mlc{QDRizszN NE\LU29USU6JRWK=
LS-123 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;UTWM2OD1zOD63PVAyKM7:TR?= NGnNV21USU6JRWK=
D-502MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnThTWM2OD1zOD64NVM6KM7:TR?= NFrv[|NUSU6JRWK=
RO82-W-1 MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF6LkiyPFgh|ryP NXnrXo5JW0GQR1XS
HuO9 NYXLZXR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXrTWM2OD1zOT6xN|c6KM7:TR?= Ml;0V2FPT0WU
ETK-1 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:4TWM2OD1zOT6xPFI4KM7:TR?= M4HweHNCVkeHUh?=
SNU-387 NITyU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\ETWM2OD1zOT6xPFg6KM7:TR?= NETZPJdUSU6JRWK=
SW1573 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF7LkG5Olkh|ryP Ml\2V2FPT0WU
NTERA-S-cl-D1 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\z[oJNUUN3ME2xPU4zODB5IN88US=> M{TRdnNCVkeHUh?=
SF126 NVjvSGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nJUWlEPTB;MUmuN|UxOiEQvF2= M33lbHNCVkeHUh?=
Calu-3 M{T4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP0TWM2OD1zOT60NlM4KM7:TR?= NGfBZldUSU6JRWK=
NCI-H1048 NXnGWng1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi5fHFKSzVyPUKwMlMzPjZizszN NVvUTXFbW0GQR1XS
NCI-H226 M4f6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LBdmlEPTB;MkCuOFM6QSEQvF2= NF;ze3NUSU6JRWK=
FTC-133 M3HNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJyLkS3NFMh|ryP NVezRZpEW0GQR1XS
SF539 NIXvTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIToenRKSzVyPUKwMlUyPzJizszN NF;TPYpUSU6JRWK=
TE-6 NVXkNWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOy[YhFUUN3ME2yNE45ODZ5IN88US=> NYj3XFBVW0GQR1XS
UMC-11 M1Pie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Sxd2lEPTB;MkCuPVE3PCEQvF2= M1KxUXNCVkeHUh?=
Becker NUjyN3JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1cmlEPTB;MkGuNVEyQCEQvF2= MXfTRW5ITVJ?
KP-4 M4DhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJzLkGxPVYh|ryP MoPzV2FPT0WU
ChaGo-K-1 NF3KfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rzXGlEPTB;MkGuN|YzPyEQvF2= M3;tT3NCVkeHUh?=
CFPAC-1 NGHncndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJzLkO4OVgh|ryP M1fROXNCVkeHUh?=
A498 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHqTWM2OD1{MT61N|EzKM7:TR?= NXj4OldSW0GQR1XS
NCI-H1755 M{\ET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3vcIVUUUN3ME2yNU43PzRzIN88US=> MW\TRW5ITVJ?
TI-73 NYryT4EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP1TWM2OD1{Mj6zNlgh|ryP MXnTRW5ITVJ?
NCI-H441 MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv3VIJ4UUN3ME2yNk42Pjh7IN88US=> MnfBV2FPT0WU
CaR-1 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ|LkCyNVMh|ryP MlTCV2FPT0WU
HCC1806 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfsTWM2OD1{Mz6wOVg{KM7:TR?= MmfVV2FPT0WU
SNU-449 M2DZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ|LkOyPUDPxE1? MnLHV2FPT0WU
EKVX M2DQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PkXmlEPTB;MkOuN|kxQSEQvF2= MXHTRW5ITVJ?
DMS-114 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\LTWM2OD1{Mz61O|Y2KM7:TR?= NUjLZ2U1W0GQR1XS
A704 NYTqbHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DXVGlEPTB;MkOuOlExOyEQvF2= NGrhbYFUSU6JRWK=
LC-2-ad NVTTXVNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PtO2lEPTB;MkOuOlE1PyEQvF2= NIrT[FNUSU6JRWK=
VM-CUB-1 M1nMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ|LkezOFEh|ryP NXvoU4NDW0GQR1XS
PC-3 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[xUopKSzVyPUK0MlA2OjZizszN MoLpV2FPT0WU
HEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr1TWM2OD1{ND6wPFY2KM7:TR?= MkP4V2FPT0WU
ABC-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDLVo9KSzVyPUK0MlI4OjlizszN MUDTRW5ITVJ?
COLO-680N M1;tWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJ2LkS3OlQh|ryP MYjTRW5ITVJ?
MZ1-PC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLYR2VKSzVyPUK0MlY5PyEQvF2= NGf4VY1USU6JRWK=
NCI-H69 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomxTWM2OD1{ND63N|U1KM7:TR?= MV\TRW5ITVJ?
TE-1 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW5TWM2OD1{NT6wOFk6KM7:TR?= MY\TRW5ITVJ?
EW-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi5NoxKSzVyPUK1MlEyOyEQvF2= M1jFb3NCVkeHUh?=
PANC-08-13 NWD2VYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ3LkixNFMh|ryP NXzRWVdHW0GQR1XS
NMC-G1 NGrPVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfDeYxMUUN3ME2yOk4xODh6IN88US=> MnGxV2FPT0WU
BT-20 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLn[FFrUUN3ME2yOk41PTR|IN88US=> MWPTRW5ITVJ?
TGBC24TKB MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\0TmlEPTB;Mk[uO|M{OSEQvF2= NXjIToNFW0GQR1XS
TE-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ4Lkm4PVUh|ryP M3jE[HNCVkeHUh?=
ESS-1 NF3OOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\mWWlEPTB;MkeuN|IyPiEQvF2= NX7iTolGW0GQR1XS
JVM-3 M{\Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX4TXFJUUN3ME2yO{43PDd3IN88US=> MoTNV2FPT0WU
C3A MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPSU5FKSzVyPUK3Mlg1QTZizszN NFLVWWZUSU6JRWK=
MDA-MB-157 NV7qVJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\OTWM2OD1{Nz64O|U{KM7:TR?= MmDhV2FPT0WU
KLE M1vCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ6LkGwOVgh|ryP NVzYWo1KW0GQR1XS
ES1 NG\3emZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ6LkG4N|gh|ryP MYPTRW5ITVJ?
CAL-120 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3jRYdXUUN3ME2yPE4{QTl7IN88US=> NVy3NVg5W0GQR1XS
NCI-N87 NV;BfFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDuTWM2OD1{OD61NVA2KM7:TR?= NFn5V2tUSU6JRWK=
RPMI-8226 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHRXItKSzVyPUK5MlE5PDNizszN M3XtfXNCVkeHUh?=
COR-L88 M{TPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDaNXlKSzVyPUK5MlI1OTlizszN NV2wcmZGW0GQR1XS
UACC-893 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GxVWlEPTB;MkmuN|E{PyEQvF2= NFPrdWxUSU6JRWK=
C8166 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ7Lkm5PVYh|ryP NUH6UlBxW0GQR1XS
J82 M4rLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TJSWlEPTB;M{CuPFE1PyEQvF2= M3PlOHNCVkeHUh?=
PFSK-1 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i1UGlEPTB;M{GuNFY2QSEQvF2= M13MNXNCVkeHUh?=
COLO-684 NFraeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvBUJZXUUN3ME2zNU41Ozd2IN88US=> NGHVdnZUSU6JRWK=
CAL-72 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfnOGVKSzVyPUOxMlU4OjlizszN NH7oZ4pUSU6JRWK=
SNB75 NFLZbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M120fGlEPTB;M{GuPFk4KM7:TR?= MoHDV2FPT0WU
MDA-MB-415 NGDuU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNzLkm3OlIh|ryP M{XGNnNCVkeHUh?=
SiHa M3zwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fHOGlEPTB;M{KuOFcyOSEQvF2= MlPOV2FPT0WU
NCI-H1648 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrRV4FKSzVyPUOyMlk{PDVizszN NGr5b5RUSU6JRWK=
EFO-21 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWyTWM2OD1|Mz6wNFUh|ryP NH3VcG5USU6JRWK=
HCC38 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\3dppKSzVyPUOzMlM5PDFizszN NEfpUlBUSU6JRWK=
IA-LM NGDHRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHRRnpKSzVyPUOzMlc5QDlizszN MYLTRW5ITVJ?
CTV-1 NGDJWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TKTGlEPTB;M{OuPVc5PiEQvF2= NHvQPZlUSU6JRWK=
NCI-H446 M3r0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPVRZM4UUN3ME2zOE4zPjh7IN88US=> M2SxbHNCVkeHUh?=
IST-SL1 NHjHcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq1eXJKSzVyPUO0Mlc1ODhizszN M4DRc3NCVkeHUh?=
EW-22 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPGTWM2OD1|ND63O|U6KM7:TR?= NFewNllUSU6JRWK=
JEG-3 NV3HTmFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmxUGVKSzVyPUO2MlE4PjZizszN MYnTRW5ITVJ?
LU-65 NF\5V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD1|Nj6yPVg2KM7:TR?= NXX4cIw1W0GQR1XS
NCI-H596 M4C2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;IfWlEPTB;M{[uPVU6OSEQvF2= MULTRW5ITVJ?
KNS-81-FD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ez[WlEPTB;M{euNVQ2KM7:TR?= NF3TW3lUSU6JRWK=
NCI-H1793 M3SyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrpOpBIUUN3ME2zO{44ODh4IN88US=> M{S1UHNCVkeHUh?=
NCI-H460 M2Djdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnhTWM2OD1|OD6wPFc{KM7:TR?= Mon3V2FPT0WU
MPP-89 M{CwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfmVFJtUUN3ME2zPU42QDh4IN88US=> NIXNb4lUSU6JRWK=
D-542MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTN7Lki0N|Yh|ryP MkDYV2FPT0WU
JAR M1XKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTRyLkS3NFUh|ryP MU\TRW5ITVJ?
NCI-H209 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP4TWM2OD12MD62O|ch|ryP MVLTRW5ITVJ?
G-402 NYjiTG51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSzTWM2OD12MT6zPVk{KM7:TR?= NV3yUYJKW0GQR1XS
IST-MES1 NF\xSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HsTGlEPTB;NEKuNVk{PSEQvF2= Mo\BV2FPT0WU
Daoy M2PvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTR{LkW0O|Eh|ryP MYTTRW5ITVJ?
EW-11 NVXBR2hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHsRXVbUUN3ME20N{4yOjFzIN88US=> NVW1S49mW0GQR1XS
Saos-2 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR|LkG1N|ch|ryP MmrhV2FPT0WU
no-10 NIO0XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILBbIxKSzVyPUSzMlE4ODJizszN M2LoVXNCVkeHUh?=
HCC1395 M1LMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\1b2lEPTB;NEOuOFY1PCEQvF2= M3\STnNCVkeHUh?=
HCE-4 NF\aUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTR|Lke2OlQh|ryP NG\MUnBUSU6JRWK=
EW-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTR|LkiwOFkh|ryP NET3cJJUSU6JRWK=
OCUB-M NVPhOZpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPGTWM2OD12ND6zOlM5KM7:TR?= M4PHc3NCVkeHUh?=
IGR-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrDVJNKSzVyPUS0MlQyOTVizszN NYT1V|ZsW0GQR1XS
NCI-H1838 M{S5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XMPWlEPTB;NESuOFM1QSEQvF2= NFHBNGdUSU6JRWK=
NCI-H2405 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7weYFKSzVyPUS0MlU{PCEQvF2= NVPRdmJwW0GQR1XS
GB-1 NIHUfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLzUWNKSzVyPUS0Mlc1PjNizszN MVnTRW5ITVJ?
MG-63 NH3yfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\nTWM2OD12Nj6wOlk3KM7:TR?= MmLJV2FPT0WU
KP-N-YN NHHCT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjLNHRKSzVyPUS2MlQ3PzlizszN NGrxOndUSU6JRWK=
no-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR5LkCyOFQh|ryP MWfTRW5ITVJ?
SW948 NXq4eXNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzYcpNKSzVyPUS3MlM{PzdizszN NGHhUFdUSU6JRWK=
CAMA-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6wT4VzUUN3ME20O{4{PDN6IN88US=> Mn;ZV2FPT0WU
HCC1187 NIrY[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\6TWM2OD12Nz61NUDPxE1? NF63Z2lUSU6JRWK=
D-392MG M4jRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR5Lk[1NVYh|ryP NVn1RYFLW0GQR1XS
647-V MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nTbWlEPTB;NEmuN|QyPCEQvF2= M1ruVXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay
+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research
+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID